Initial Statement of Beneficial Ownership (3)
May 05 2017 - 6:14PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Dillon Michael J.
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
5/1/2017
|
3. Issuer Name
and
Ticker or Trading Symbol
PLx Pharma Inc. [PLXP]
|
(Last)
(First)
(Middle)
8285 EL RIO STREET, STE. 130
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___
X
___ Officer (give title below)
_____ Other (specify below)
VP, Sales and Marketing /
|
(Street)
HOUSTON, TX 77054
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Employee Stock Option
|
5/1/2018
(1)
|
5/1/2027
|
Common Stock
|
45000
|
$7.975
|
D
|
|
Explanation of Responses:
|
(1)
|
The Reporting Person was awarded 45,000 employee stock options on May 1, 2017 under the Issuer's 2015 Omnibus Incentive Plan. One-third of the grant becomes exercisable on the first anniversary of the grant date, with the remainder becoming exercisable in quarterly installments over the next two years following the first anniversary of the grant date.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Dillon Michael J.
8285 EL RIO STREET
STE. 130
HOUSTON, TX 77054
|
|
|
VP, Sales and Marketing
|
|
Signatures
|
Natasha Giordano, as Attorney-in-Fact for Michael J. Dillon
|
|
5/5/2017
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Apr 2023 to Apr 2024